Hepatoma-Derived Growth Factor Is a Novel Prognostic Factor for Patients with Pancreatic Cancer
| Autor: | Hirokazu Uyama, Morito Monden, Shoji Nakamori, Hirayuki Enomoto, Ichiro Kawase, Masato Sakon, Norio Hayashi, Yasuhiko Tomita, Yoshihiko Hoshida, Hideji Nakamura, Yorihide Okuda, Katsuyuki Aozasa, Binglin Zhang |
|---|---|
| Rok vydání: | 2006 |
| Předmět: |
Cancer Research
Pathology medicine.medical_specialty Pancreatic disease Pancreatic cancer medicine Humans Aged Proportional Hazards Models Analysis of Variance business.industry Middle Aged Hepatoma-derived growth factor Ductal carcinoma Prognosis medicine.disease Immunohistochemistry Survival Analysis Pancreatic Neoplasms Treatment Outcome medicine.anatomical_structure Oncology Hepatocellular carcinoma Multivariate Analysis Cancer cell Intercellular Signaling Peptides and Proteins business Pancreas Carcinoma Pancreatic Ductal |
| Zdroj: | Clinical Cancer Research. 12:6043-6048 |
| ISSN: | 1557-3265 1078-0432 |
| Popis: | Purpose: Hepatoma-derived growth factor (HDGF) is a nucleus-targeted growth factor playing an important role in the development and progression of cancers. This study investigated the correlation of HDGF expression and prognosis in patients with pancreatic ductal carcinoma. Patients and Methods: HDGF expression in pancreatic cancer cell lines was analyzed by Western blotting. HDGF expression was analyzed by immunohistochemistry for 50 patients with primary ductal carcinoma of the pancreas (33 male and 17 female) ranging in age from 48 to 80 years (median, 65 years) receiving surgical treatment. Cancer cells showing stronger staining than the noncancerous ducts were regarded as positive. Cases showing positive staining in 90% of tumor cells were regarded as HDGF labeling index (LI) levels 1 and 2, respectively. HDGF LI was determined separately for the nucleus and the cytoplasm. Results: Western blotting showed HDGF expression in pancreatic cancer cells similar to that of hepatic cell lines. Twenty-three (46%) and 27 (54%) cases and 22 (44%) and 28 (56%) cases showed HDGF LI levels 1 and 2 for the nucleus and the cytoplasm, respectively. Patients with nuclear HDGF LI level 1 showed a significantly better 5-year survival rate (37.0%) than those with level 2 (6.8%; P = 0.023). No significant difference was observed in the cytoplasmic HDGF LI classification. Multivariate analysis revealed nuclear HDGF LI to be an independent prognosticator. Conclusions: These findings suggest that HDGF could be a novel prognostic factor for pancreatic ductal carcinoma. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|